Global PDGFR Inhibitors Market, Drug Sales & Clinical Trials Insight 2026
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global PDGFR Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights:
Avapritinib sold under brand name Ayvakit is the first approved PDGFR inhibitor available in market. The drug was developed by Blueprint Medicines and is mainly indicated for the treatment of gastrointestinal tumors (GIST) and mastocytosis. The FDA approval of Ayvakit represents a major breakthrough in the treatment of rare GIST. Since it introduction into the market, the drug has shown high adoption rates among patients worldwide. The rise in prevalence of cancer and high medical needs for targeted therapy associated with increasing awareness regarding the availability of drug will further enhance its growth in market for next few years.
In the same year, Ripretinib sold under brand name Qinlcok has also gained approval. The drug is developed by Deciphera Pharmaceuticals and is indicated for the treatment of gastrointestinal tumors. In short span of time, the drug has shown robust sales in the global market. Owing to its high specificity towards PDGFR and ability to target broad spectrum of kinases, it is expected that the drug will dominate the overall PDGFR inhibitor market in coming years. Although the market is poised to growth in coming years but several factors limits their growth in market. The high cost of cancer therapy is one of the major limiting factors which will restrict the growth of market in coming years.
Presently, several companies including well-established players and new entrants are actively engaged in developing PGFR inhibitors for a wide range of disease indications. Innovation in this field is mostly focused on improving the therapeutic efficacy, safety, and overall survival rate. This sector has particularly gained significant attention from private and public investors, which have extended their financial support to capable developer companies. The market also witnessed substantial partnership activity over the last few years.
In coming years, the global market will witness significant rise in the prevalence of cancers attributing to several factors including rising geriatric population, smoking, drinking, physical inactivity, and poor diet. This will increase the demand of targeted therapies, thus driving the growth of PDGFR inhibitor market. In addition to two approved drugs, the pharmaceutical companies have developed several potential PGFR inhibitors including Crenolanib, Tovetumab, Seralutinib, ARRY-768, CP-673451, and MTLH001 which are expected to enter the market during the forecast period, thus boosting the growth of market.
As per report findings, the global PDGFR inhibitor market will grow with CAGR of 92% and is expected to reach around US$ 4 Billion by 2026. The high growth in the market can be justified by the extensive research and development in this sector and high adoption rates of approved drugs. In addition to this, the rising initiative by government and the development of favorable reimbursement policies will also ensure the high uptake of the drug in the market. Regionally, US is expected to dominate the market owing to large target population base, increasing adoption rates to novel therapies, and high concentration of pharmaceutical companies which actively indulge in research and development sector. Apart from this, Asia-Pacific region is also expected to exhibit high CAGR rates due to increased healthcare spending and presence of several untapped opportunities.
Global PDGFR Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global PDGFR Inhibitors Market Opportunity Assessment: > USD 4 Billion
- Market & Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 2 (Lartruvo & Ayvakit)
- Approved PGDFR Drug Patent, Price & Sales insight 2020 Till 2026
- Future market Assessment By Indication & Region Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Avapritinib sold under brand name Ayvakit is the first approved PDGFR inhibitor available in market. The drug was developed by Blueprint Medicines and is mainly indicated for the treatment of gastrointestinal tumors (GIST) and mastocytosis. The FDA approval of Ayvakit represents a major breakthrough in the treatment of rare GIST. Since it introduction into the market, the drug has shown high adoption rates among patients worldwide. The rise in prevalence of cancer and high medical needs for targeted therapy associated with increasing awareness regarding the availability of drug will further enhance its growth in market for next few years.
In the same year, Ripretinib sold under brand name Qinlcok has also gained approval. The drug is developed by Deciphera Pharmaceuticals and is indicated for the treatment of gastrointestinal tumors. In short span of time, the drug has shown robust sales in the global market. Owing to its high specificity towards PDGFR and ability to target broad spectrum of kinases, it is expected that the drug will dominate the overall PDGFR inhibitor market in coming years. Although the market is poised to growth in coming years but several factors limits their growth in market. The high cost of cancer therapy is one of the major limiting factors which will restrict the growth of market in coming years.
Presently, several companies including well-established players and new entrants are actively engaged in developing PGFR inhibitors for a wide range of disease indications. Innovation in this field is mostly focused on improving the therapeutic efficacy, safety, and overall survival rate. This sector has particularly gained significant attention from private and public investors, which have extended their financial support to capable developer companies. The market also witnessed substantial partnership activity over the last few years.
In coming years, the global market will witness significant rise in the prevalence of cancers attributing to several factors including rising geriatric population, smoking, drinking, physical inactivity, and poor diet. This will increase the demand of targeted therapies, thus driving the growth of PDGFR inhibitor market. In addition to two approved drugs, the pharmaceutical companies have developed several potential PGFR inhibitors including Crenolanib, Tovetumab, Seralutinib, ARRY-768, CP-673451, and MTLH001 which are expected to enter the market during the forecast period, thus boosting the growth of market.
As per report findings, the global PDGFR inhibitor market will grow with CAGR of 92% and is expected to reach around US$ 4 Billion by 2026. The high growth in the market can be justified by the extensive research and development in this sector and high adoption rates of approved drugs. In addition to this, the rising initiative by government and the development of favorable reimbursement policies will also ensure the high uptake of the drug in the market. Regionally, US is expected to dominate the market owing to large target population base, increasing adoption rates to novel therapies, and high concentration of pharmaceutical companies which actively indulge in research and development sector. Apart from this, Asia-Pacific region is also expected to exhibit high CAGR rates due to increased healthcare spending and presence of several untapped opportunities.
1. INTRODUCTION TO PDGFR INHIBITORS
1.1 Overview
1.2 Evolution of PDGFR Inhibitors
2. PDGFR INHIBITORS - MECHANISM OF ACTION
2.1 General Functions & Mechanism
2.2 Approved Drugs Mechanism of Action
3. PDGFR POTENTIAL TARGET FOR LEADING PATHOLOGICAL CONDITIONS
4. ROLE OF PDGFR INHIBITORS IN CANCER
5. GLOBAL PDGFR INHIBITORS CLINICAL TRIALS INSIGHT
5.1 By Phase
5.2 By Development Status
5.3 By Region
6. GLOBAL PDGFR INHIBITOR MARKET INSIGHT
6.1 Market Overview
6.2 Current Market Scenario
7. PDGFR INHIBITOR REGIONAL MARKET ANALYSIS
7.1 US
7.2 Europe
7.3 China
7.4 Japan
7.5 ROW
8. PDGFR INHIBITOR MARKET OPPORTUNITY BY INDICATION
8.1 Gastrointestinal Stromal Tumors
8.2 Glioma
8.3 Colorectal Cancer
8.4 Leukemia
8.5 Lung Cancer
9. LARTRUVO (OLARATUMAB) 1ST APPROVED PDGFR INHIBITOR (2016) & MARKET WITHDRAWAL (2019)
9.1 Overview
9.2 Dosage, Price & Sales Analysis
10. AYVAKIT (AVAPRITINIB) 2ND APPROVED PDGFR INHIBITOR (2020)
10.1 Overview
10.2 Patents & Assignees
11. AYVAKIT COMMERCIAL INSIGHT
11.1 Price & Dosage
11.2 Sales Analysis
12. QINLOCK (RIPRETINIB) 3RD APPROVED PDGFR INHIBITOR (2020)
12.1 Overview
12.2 Patents & Assignees
13. QINLOCK COMMERCIAL INSIGHT
13.1 Price & Dosage
13.2 Sales Analysis
14. PDGFR INHIBITORS SALES FORECAST 2026
14.1 Ayvakit Sales Forecast
14.2 Qinlock Sales Forecast
15. PDGFR INHIBITOR FUTURE MARKET PERSPECTIVES
16. GLOBAL PDGFR INHIBITORS MARKET DYNAMICS
16.1 Market Drivers
16.2 Market Challenges
17. COMPETITIVE LANDSCAPE
17.1 Arog Pharmaceuticals, Inc
17.2 AstraZeneca
17.3 Bayer
17.4 Blueprint Medicine
17.5 Boehringer Ingelheim
17.6 Clovis Oncology
17.7 Deciphera Pharmaceuticals
17.8 Eli Lilly
17.9 Gilead Sciences
17.10 Pfizer
17.11 Tyrogenex
17.12 Zai Lab
1.1 Overview
1.2 Evolution of PDGFR Inhibitors
2. PDGFR INHIBITORS - MECHANISM OF ACTION
2.1 General Functions & Mechanism
2.2 Approved Drugs Mechanism of Action
3. PDGFR POTENTIAL TARGET FOR LEADING PATHOLOGICAL CONDITIONS
4. ROLE OF PDGFR INHIBITORS IN CANCER
5. GLOBAL PDGFR INHIBITORS CLINICAL TRIALS INSIGHT
5.1 By Phase
5.2 By Development Status
5.3 By Region
6. GLOBAL PDGFR INHIBITOR MARKET INSIGHT
6.1 Market Overview
6.2 Current Market Scenario
7. PDGFR INHIBITOR REGIONAL MARKET ANALYSIS
7.1 US
7.2 Europe
7.3 China
7.4 Japan
7.5 ROW
8. PDGFR INHIBITOR MARKET OPPORTUNITY BY INDICATION
8.1 Gastrointestinal Stromal Tumors
8.2 Glioma
8.3 Colorectal Cancer
8.4 Leukemia
8.5 Lung Cancer
9. LARTRUVO (OLARATUMAB) 1ST APPROVED PDGFR INHIBITOR (2016) & MARKET WITHDRAWAL (2019)
9.1 Overview
9.2 Dosage, Price & Sales Analysis
10. AYVAKIT (AVAPRITINIB) 2ND APPROVED PDGFR INHIBITOR (2020)
10.1 Overview
10.2 Patents & Assignees
11. AYVAKIT COMMERCIAL INSIGHT
11.1 Price & Dosage
11.2 Sales Analysis
12. QINLOCK (RIPRETINIB) 3RD APPROVED PDGFR INHIBITOR (2020)
12.1 Overview
12.2 Patents & Assignees
13. QINLOCK COMMERCIAL INSIGHT
13.1 Price & Dosage
13.2 Sales Analysis
14. PDGFR INHIBITORS SALES FORECAST 2026
14.1 Ayvakit Sales Forecast
14.2 Qinlock Sales Forecast
15. PDGFR INHIBITOR FUTURE MARKET PERSPECTIVES
16. GLOBAL PDGFR INHIBITORS MARKET DYNAMICS
16.1 Market Drivers
16.2 Market Challenges
17. COMPETITIVE LANDSCAPE
17.1 Arog Pharmaceuticals, Inc
17.2 AstraZeneca
17.3 Bayer
17.4 Blueprint Medicine
17.5 Boehringer Ingelheim
17.6 Clovis Oncology
17.7 Deciphera Pharmaceuticals
17.8 Eli Lilly
17.9 Gilead Sciences
17.10 Pfizer
17.11 Tyrogenex
17.12 Zai Lab
LIST OF FIGURES
Figure 1-1: Evolution of PDGFR Inhibitors
Figure 2-1: PDGFR’s Pathway, Receptors, Ligands & Functions
Figure 2-2: PDGFR Stimulated Effectors, Biomarkers & Cell Signaling Pathways
Figure 2-3: PDGFR Inhibitors – Mechanism of Action
Figure 2-4: Ayvakit - Mechanism of Action
Figure 2-5: Qinlok – Mechanism of Action
Figure 2-6: Lartruvo – Mechanism of Action
Figure 3-1: Role of PDGFR Inhibitors in Neurological Disorders
Figure 3-2: Potential Role of PDGFR Inhibitors in Asthma
Figure 4-1: PDGF Signaling in Cancer Progression
Figure 5-1: Global – Number of PDGFR Inhibitors Related Clinical Trials by Phase, October’2021
Figure 5-2: Global – PDGFR Inhibitors Related Clinical Trials by Phase (%), October’2021
Figure 5-3: Global – Number of PDGFR Inhibitors Related Clinical Trials by Development Status, October’2021
Figure 5-4: Global – Number of PDGFR Inhibitors Related Clinical Trials by Development Status (%), October’2021
Figure 5-5: Global – Number of PDGFR Inhibitors Related Clinical Trials by Region, October’2021
Figure 6-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 6-2: Global – PDGFR Inhibitor Market by Product (%), 2020
Figure 6-3: Global – PDGFR Inhibitor Market by Product (%), H1’2021
Figure 6-4: Global – PDGFR Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 6-5: PDGFR Inhibitor - Market by Region (US$ Million), 2020
Figure 6-6: PDGFR Inhibitor - Market by Region (%), 2020
Figure 6-7: PDGFR Inhibitor - Market by Region (US$ Million), H1’2021
Figure 6-8: PDGFR Inhibitor - Market by Region (%), H1’2021
Figure 7-1: US – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 7-2: PDGFR Inhibitor Market – US vs. ROW (US$ Million), 2020
Figure 7-3: PDGFR Inhibitor Market – US vs. ROW (%), 2020
Figure 7-4: PDGFR Inhibitor Market – US vs. ROW (US$ Million), H1’2021
Figure 7-5: PDGFR Inhibitor Market – US vs. ROW (%), H1’2021
Figure 7-6: US – PDGFR Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 7-7: Europe – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 7-8: Europe – Cancer Incidences by Country (Million), 2020
Figure 7-9: PDGFR Inhibitor Market – Europe vs. ROW (US$ Million), 2020
Figure 7-10: PDGFR Inhibitor Market – Europe vs. ROW (%), 2020
Figure 7-11: Europe – PDGFR Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 7-12: China – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 7-13: China – PDGFR Inhibitor Market Size (US$ Million), 2021 - 2026
Figure 7-14: Japan – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 7-15: Japan – PDGFR Inhibitor Market Size (US$ Million), 2022 - 2026
Figure 7-16: Cancer – Incidences by Region, 2020
Figure 7-17: ROW – PDGFR Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 8-1: Global – Estimated GIST Cancer Cases, 2020 - 2026
Figure 8-2: Global – PDGFR Inhibitor Market Opportunity in GIST by 5% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-3: Global – PDGFR Inhibitor Market Opportunity in GIST by 10% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-4: Global – PDGFR Inhibitor Market Opportunity in GIST by 15% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-5: Global – PDGFR Inhibitor Market Opportunity in GIST by 20% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-6: Global – PDGFR Inhibitor Market Opportunity in GIST by 25% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-7: Global – PDGFR Inhibitor Market Opportunity in GIST by 30% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-8: Global – PDGFR Inhibitor Market Opportunity in GIST by 35% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-9: Global – PDGFR Inhibitor Market Opportunity in GIST by 40% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-10: Global – PDGFR Inhibitor Market Opportunity in GIST by 45% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-11: Global – PDGFR Inhibitor Market Opportunity in GIST by 50% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-12: Global – Estimated Glioma Cancer Cases, 2020 - 2026
Figure 8-13: Global – PDGFR Inhibitor Market Opportunity in Glioma by 2% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-14: Global – PDGFR Inhibitor Market Opportunity in Glioma by 4% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-15: Global – PDGFR Inhibitor Market Opportunity in Glioma by 6% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-16: Global – PDGFR Inhibitor Market Opportunity in Glioma by 8% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-17: Global – PDGFR Inhibitor Market Opportunity in Glioma by 10% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-18: Global – PDGFR Inhibitor Market Opportunity in Glioma by 12% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-19: Global – PDGFR Inhibitor Market Opportunity in Glioma by 14% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-20: Global – PDGFR Inhibitor Market Opportunity in Glioma by 16% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-21: Global – PDGFR Inhibitor Market Opportunity in Glioma by 18% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-22: Global – PDGFR Inhibitor Market Opportunity in Glioma by 20% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-23: Global – Estimated Colorectal Cancer Cases, 2020-2026
Figure 8-24: Global – Estimated Metastatic Colorectal Cancer Cases, 2020-2026
Figure 8-25: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 1% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-26: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 2% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-27: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 3% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-28: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 4% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-29: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 5% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-30: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 6% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-31: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 7% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-32: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 8% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-33: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 9% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-34: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 10% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-35: Global – Estimated Leukemia Cancer Cases, 2020 - 2026
Figure 8-36: Global – Estimated Acute Myeloid Leukemia Cancer Cases, 2020 - 2026
Figure 8-37: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 1% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-38: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 2% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-39: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 3% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-40: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 4% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-41: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 5% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-42: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 6% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-43: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 7% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-44: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 8% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-45: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 9% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-46: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 10% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-47: Global – Estimated Lung Cancer Cases, 2020 - 2026
Figure 8-48: Global – Estimated PDGFR Mutated Lung Cancer Cases, 2021 - 2026
Figure 8-49: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 1% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-50: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 2% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-51: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 3% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-52: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 4% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-53: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 5% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-54: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 6% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-55: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 7% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-56: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 8% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-57: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 9% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-58: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 10% Adoption Rate (US$ Million), 2021 - 2026
Figure 9-1: Lartruvo – Approval Year by Region
Figure 9-2: Lartruvo – FDA Approval & Orphan Designation Year
Figure 9-3: Lartruvo – Compound Patent & Biological Data Package Protection Expiration Year
Figure 9-4: Lartruvo – Market Approval & Withdrawal Year
Figure 9-5: Lartruvo – Price for 19ml Supply & Price per ml of Intravenous Solution (US$), October’2021
Figure 9-6: Lartruvo – Price for 50ml Supply & Price per ml of Intravenous Solution (US$), October’2021
Figure 9-7: Lartruvo – Average Cost of Single Dose & Single Treatment Cycle (US$), October’2021
Figure 9-8: Global – Lartruvo Annual Sales (US$ Million), 2017 & 2018
Figure 10-1: Ayvakit – Orphan Drug Designation by Region
Figure 10-2: US - Ayvakit FDA Approval Year by Indication
Figure 10-3: Ayvakit – Approval Year by Region
Figure 10-4: US – Avyakit Patent Approval & Expiration Year
Figure 11-1: US – Cost of Supply of 30 Tablets & Per Unit Cost of Ayvakit Oral Tablet (US$), October’2021
Figure 11-2: Europe – Cost of Supply of 30 Tablets & Per Unit Cost of Ayvakit Oral Tablet (Euro/US$), October’2021
Figure 11-3: Ayvakit – Recommended Initial & Reduced Dose in Patients with GIST (mg)
Figure 11-4: US – Average Cost of Daily, Monthly & Annual Treatment with Ayvakit (US$)
Figure 11-5: Global – Ayvakit Quarterly Sales (US$ Million), 2020
Figure 11-6: Global – Ayvakit Quarterly Sales (US$ Million), Q1 - Q3’2021
Figure 12-1: US - Qinlock Orphan Drug Designation & FDA Approval Year
Figure 12-2: Qinlock – Approval Year by Region
Figure 12-3: US – Qinlock Patent Approval & Expiration Year
Figure 12-4: Canada - Qinlock Patent Approval & Expiration Year
Figure 13-1: US – Cost of Supply of 90 Tablets & Per Unit Cost of Qinlock 50mg Oral Tablet (US$), October’2021
Figure 13-2: Qinlock – Recommended Initial & Reduced Dose in Patients with GIST (mg)
Figure 13-3: US – Average Cost of Daily, Monthly & Annual Treatment with Qinlock (US$)
Figure 13-4: Global – Qinlock Quarterly Sales (US$ Million), Q2-Q4’2020
Figure 13-5: US – Qinlock Quarterly Sales (US$ Million), Q2-Q4’2020
Figure 13-6: Qinlock Quarterly Sales by Region (US$ Million), Q2-Q4’2020
Figure 13-7: Qinlock Quarterly Sales by Region (%), Q2-Q4’2020
Figure 13-8: Global – Qinlock Quarterly Sales (US$ Million), Q1 & Q2’2021
Figure 13-9: US – Qinlock Quarterly Sales (US$ Million), Q1 & Q2’2021
Figure 13-10: Qinlock – Half Year Sales by Region (US$ Million), H1’2021
Figure 13-11: Qinlock – Half Year Sales by Region (%), H1’2021
Figure 14-1: Global – Ayvakit Sales Forecast (US$ Million), 2021 - 2026
Figure 14-2: Global – Qinlock Sales Forecast (US$ Million), 2021 - 2026
Figure 14-3: US – Qinlock Sales Forecast (US$ Million), 2021 - 2026
Figure 14-4: ROW – Qinlock Sales Forecast (US$ Million), 2021 - 2026
Figure 16-1: Global PDGFR Inhibitors Market Drivers
Figure 16-2: Challenges for Global PDGFR Inhibitors Market
Figure 16-3: US – Annual Treatment Cost Comparison of PDGRF Inhibitors with Other Treatments (US$), October’2021
Figure 1-1: Evolution of PDGFR Inhibitors
Figure 2-1: PDGFR’s Pathway, Receptors, Ligands & Functions
Figure 2-2: PDGFR Stimulated Effectors, Biomarkers & Cell Signaling Pathways
Figure 2-3: PDGFR Inhibitors – Mechanism of Action
Figure 2-4: Ayvakit - Mechanism of Action
Figure 2-5: Qinlok – Mechanism of Action
Figure 2-6: Lartruvo – Mechanism of Action
Figure 3-1: Role of PDGFR Inhibitors in Neurological Disorders
Figure 3-2: Potential Role of PDGFR Inhibitors in Asthma
Figure 4-1: PDGF Signaling in Cancer Progression
Figure 5-1: Global – Number of PDGFR Inhibitors Related Clinical Trials by Phase, October’2021
Figure 5-2: Global – PDGFR Inhibitors Related Clinical Trials by Phase (%), October’2021
Figure 5-3: Global – Number of PDGFR Inhibitors Related Clinical Trials by Development Status, October’2021
Figure 5-4: Global – Number of PDGFR Inhibitors Related Clinical Trials by Development Status (%), October’2021
Figure 5-5: Global – Number of PDGFR Inhibitors Related Clinical Trials by Region, October’2021
Figure 6-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 6-2: Global – PDGFR Inhibitor Market by Product (%), 2020
Figure 6-3: Global – PDGFR Inhibitor Market by Product (%), H1’2021
Figure 6-4: Global – PDGFR Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 6-5: PDGFR Inhibitor - Market by Region (US$ Million), 2020
Figure 6-6: PDGFR Inhibitor - Market by Region (%), 2020
Figure 6-7: PDGFR Inhibitor - Market by Region (US$ Million), H1’2021
Figure 6-8: PDGFR Inhibitor - Market by Region (%), H1’2021
Figure 7-1: US – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 7-2: PDGFR Inhibitor Market – US vs. ROW (US$ Million), 2020
Figure 7-3: PDGFR Inhibitor Market – US vs. ROW (%), 2020
Figure 7-4: PDGFR Inhibitor Market – US vs. ROW (US$ Million), H1’2021
Figure 7-5: PDGFR Inhibitor Market – US vs. ROW (%), H1’2021
Figure 7-6: US – PDGFR Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 7-7: Europe – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 7-8: Europe – Cancer Incidences by Country (Million), 2020
Figure 7-9: PDGFR Inhibitor Market – Europe vs. ROW (US$ Million), 2020
Figure 7-10: PDGFR Inhibitor Market – Europe vs. ROW (%), 2020
Figure 7-11: Europe – PDGFR Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 7-12: China – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 7-13: China – PDGFR Inhibitor Market Size (US$ Million), 2021 - 2026
Figure 7-14: Japan – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 7-15: Japan – PDGFR Inhibitor Market Size (US$ Million), 2022 - 2026
Figure 7-16: Cancer – Incidences by Region, 2020
Figure 7-17: ROW – PDGFR Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 8-1: Global – Estimated GIST Cancer Cases, 2020 - 2026
Figure 8-2: Global – PDGFR Inhibitor Market Opportunity in GIST by 5% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-3: Global – PDGFR Inhibitor Market Opportunity in GIST by 10% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-4: Global – PDGFR Inhibitor Market Opportunity in GIST by 15% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-5: Global – PDGFR Inhibitor Market Opportunity in GIST by 20% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-6: Global – PDGFR Inhibitor Market Opportunity in GIST by 25% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-7: Global – PDGFR Inhibitor Market Opportunity in GIST by 30% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-8: Global – PDGFR Inhibitor Market Opportunity in GIST by 35% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-9: Global – PDGFR Inhibitor Market Opportunity in GIST by 40% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-10: Global – PDGFR Inhibitor Market Opportunity in GIST by 45% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-11: Global – PDGFR Inhibitor Market Opportunity in GIST by 50% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-12: Global – Estimated Glioma Cancer Cases, 2020 - 2026
Figure 8-13: Global – PDGFR Inhibitor Market Opportunity in Glioma by 2% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-14: Global – PDGFR Inhibitor Market Opportunity in Glioma by 4% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-15: Global – PDGFR Inhibitor Market Opportunity in Glioma by 6% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-16: Global – PDGFR Inhibitor Market Opportunity in Glioma by 8% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-17: Global – PDGFR Inhibitor Market Opportunity in Glioma by 10% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-18: Global – PDGFR Inhibitor Market Opportunity in Glioma by 12% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-19: Global – PDGFR Inhibitor Market Opportunity in Glioma by 14% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-20: Global – PDGFR Inhibitor Market Opportunity in Glioma by 16% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-21: Global – PDGFR Inhibitor Market Opportunity in Glioma by 18% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-22: Global – PDGFR Inhibitor Market Opportunity in Glioma by 20% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-23: Global – Estimated Colorectal Cancer Cases, 2020-2026
Figure 8-24: Global – Estimated Metastatic Colorectal Cancer Cases, 2020-2026
Figure 8-25: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 1% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-26: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 2% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-27: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 3% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-28: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 4% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-29: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 5% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-30: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 6% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-31: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 7% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-32: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 8% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-33: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 9% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-34: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 10% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-35: Global – Estimated Leukemia Cancer Cases, 2020 - 2026
Figure 8-36: Global – Estimated Acute Myeloid Leukemia Cancer Cases, 2020 - 2026
Figure 8-37: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 1% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-38: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 2% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-39: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 3% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-40: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 4% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-41: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 5% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-42: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 6% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-43: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 7% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-44: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 8% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-45: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 9% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-46: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 10% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-47: Global – Estimated Lung Cancer Cases, 2020 - 2026
Figure 8-48: Global – Estimated PDGFR Mutated Lung Cancer Cases, 2021 - 2026
Figure 8-49: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 1% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-50: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 2% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-51: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 3% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-52: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 4% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-53: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 5% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-54: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 6% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-55: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 7% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-56: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 8% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-57: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 9% Adoption Rate (US$ Million), 2021 - 2026
Figure 8-58: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 10% Adoption Rate (US$ Million), 2021 - 2026
Figure 9-1: Lartruvo – Approval Year by Region
Figure 9-2: Lartruvo – FDA Approval & Orphan Designation Year
Figure 9-3: Lartruvo – Compound Patent & Biological Data Package Protection Expiration Year
Figure 9-4: Lartruvo – Market Approval & Withdrawal Year
Figure 9-5: Lartruvo – Price for 19ml Supply & Price per ml of Intravenous Solution (US$), October’2021
Figure 9-6: Lartruvo – Price for 50ml Supply & Price per ml of Intravenous Solution (US$), October’2021
Figure 9-7: Lartruvo – Average Cost of Single Dose & Single Treatment Cycle (US$), October’2021
Figure 9-8: Global – Lartruvo Annual Sales (US$ Million), 2017 & 2018
Figure 10-1: Ayvakit – Orphan Drug Designation by Region
Figure 10-2: US - Ayvakit FDA Approval Year by Indication
Figure 10-3: Ayvakit – Approval Year by Region
Figure 10-4: US – Avyakit Patent Approval & Expiration Year
Figure 11-1: US – Cost of Supply of 30 Tablets & Per Unit Cost of Ayvakit Oral Tablet (US$), October’2021
Figure 11-2: Europe – Cost of Supply of 30 Tablets & Per Unit Cost of Ayvakit Oral Tablet (Euro/US$), October’2021
Figure 11-3: Ayvakit – Recommended Initial & Reduced Dose in Patients with GIST (mg)
Figure 11-4: US – Average Cost of Daily, Monthly & Annual Treatment with Ayvakit (US$)
Figure 11-5: Global – Ayvakit Quarterly Sales (US$ Million), 2020
Figure 11-6: Global – Ayvakit Quarterly Sales (US$ Million), Q1 - Q3’2021
Figure 12-1: US - Qinlock Orphan Drug Designation & FDA Approval Year
Figure 12-2: Qinlock – Approval Year by Region
Figure 12-3: US – Qinlock Patent Approval & Expiration Year
Figure 12-4: Canada - Qinlock Patent Approval & Expiration Year
Figure 13-1: US – Cost of Supply of 90 Tablets & Per Unit Cost of Qinlock 50mg Oral Tablet (US$), October’2021
Figure 13-2: Qinlock – Recommended Initial & Reduced Dose in Patients with GIST (mg)
Figure 13-3: US – Average Cost of Daily, Monthly & Annual Treatment with Qinlock (US$)
Figure 13-4: Global – Qinlock Quarterly Sales (US$ Million), Q2-Q4’2020
Figure 13-5: US – Qinlock Quarterly Sales (US$ Million), Q2-Q4’2020
Figure 13-6: Qinlock Quarterly Sales by Region (US$ Million), Q2-Q4’2020
Figure 13-7: Qinlock Quarterly Sales by Region (%), Q2-Q4’2020
Figure 13-8: Global – Qinlock Quarterly Sales (US$ Million), Q1 & Q2’2021
Figure 13-9: US – Qinlock Quarterly Sales (US$ Million), Q1 & Q2’2021
Figure 13-10: Qinlock – Half Year Sales by Region (US$ Million), H1’2021
Figure 13-11: Qinlock – Half Year Sales by Region (%), H1’2021
Figure 14-1: Global – Ayvakit Sales Forecast (US$ Million), 2021 - 2026
Figure 14-2: Global – Qinlock Sales Forecast (US$ Million), 2021 - 2026
Figure 14-3: US – Qinlock Sales Forecast (US$ Million), 2021 - 2026
Figure 14-4: ROW – Qinlock Sales Forecast (US$ Million), 2021 - 2026
Figure 16-1: Global PDGFR Inhibitors Market Drivers
Figure 16-2: Challenges for Global PDGFR Inhibitors Market
Figure 16-3: US – Annual Treatment Cost Comparison of PDGRF Inhibitors with Other Treatments (US$), October’2021
LIST OF TABLES
Table 4-1: Frequency of PDGFR by Cancer Types
Table 8-1: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in GIST, 2021 - 2026
Table 8-2: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Glioma, 2021 - 2026
Table 8-3: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Metastatic Colorectal Cancer, 2021 - 2026
Table 8-4: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Acute Myeloid Leukemia, 2021 - 2026
Table 8-5: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Lung Cancer, 2021 – 2026
Table 4-1: Frequency of PDGFR by Cancer Types
Table 8-1: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in GIST, 2021 - 2026
Table 8-2: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Glioma, 2021 - 2026
Table 8-3: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Metastatic Colorectal Cancer, 2021 - 2026
Table 8-4: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Acute Myeloid Leukemia, 2021 - 2026
Table 8-5: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Lung Cancer, 2021 – 2026
